[Indications for using trental in the initial manifestations of inadequate blood supply to the brain].
The action of trental was studied in 125 patients with initial manifestations of cerebral circulation insufficiency (CCI) secondary to vasomotor dystonia or atherosclerosis. Trental was used in the form of tablets (100 mg 3 times daily) for 60 days. To assess the therapeutic effect of trental, the authors analyzed the time-course of subjective manifestations, parameters of echopulsography of cerebral vessels and biomicroscopy of the conjunctiva, and the data of the total blood count and the rheological properties of the blood. In patients with initial manifestations of CCI trental decreased the cerebral vascular resistance and improved the venous outflow, reduced platelet adhesive and aggregation properties and diminished blood viscosity. It also elevated the spontaneous fibrinolytic activity of the blood. The advisability of selective administration of the drug for treating initial manifestations of CCI was confirmed.
D000328:Adult; D001777:Blood Coagulation; D001809:Blood Viscosity; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D010973:Platelet Adhesiveness; D010974:Platelet Aggregation; D013805:Theobromine / Q000031:analogs & derivatives*; D014655:Vascular Resistance
D013805:Theobromine; D010431:Pentoxifylline
Pokazaniia k primeneniiu trentala pri nachal'nykh proiavleniiakh nedostatochnosti krovosnabzheniia mozga.